According to Darnitsa top manager, as part of the implementation of the programme to preserve and increase the sales market volume, Darnitsa Group has taken a large market share in the Ukrainian pharmaceutical industry. The global COVID-19 pandemic certainly forced the plant's management to look for alternative approaches to production solutions. In the context of a pandemic, the concern has activated all its reserves in order to provide Ukrainian consumers with affordable medicines of its own production as much as possible.
While analysing the state of the global pharmaceutical market, Dmytro Shymkiv noted that the pharmaceuticals development and production industry is now the leader in the innovative segment. Such acknowledged authorities as Moderna, Pfizer, Novavax, Jonson & Jonson, and AstraZeneca hold top positions in the rating. These pharmaceutical corporations became leaders because they were able to develop, test, mass-produce, and market globally effective COVID-19 vaccines in less than a year. This success stimulated other pharmaceutical companies to continuously and systematically introduce new technologies in the production of medicines.
In turn, Darnitsa Group launched a non-stop innovation process, which allowed it to get significant investments in new projects and developments. This is evidenced by statistical data, according to which the concern is the leader in the domestic pharmaceutical industry in terms of the volume of products sold. Dmytro Shymkiv also stated that the traditional distrust of Ukrainians towards local pharmaceutical manufacturers is groundless. To prove his point, he announced the official data. According to them, the Ukrainian medicines produced by Darnitsa company pass the final stages of tests in the laboratories of the EU countries, fully comply with European requirements, and are successfully sold in the EU markets.
Domestic pharmaceuticals are in no way inferior to European counterparts in terms of technological processes and quality.